UNSPSC 51152059: Hexcarbacholine bromide

This classification denotes a muscle relaxant with the molecular formula C18H40N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NM87THP11P, chemically known as n,n,n,n,n,n-hexamethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecamethylendiammonium dibromid but more generally known as hexcarbacholine bromide, which bears US NIH Compound Identifier 71495. European Medicines Agency schedules Hexcarbacholine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08034MIG.

UNSPSC 51152059 Hexcarbacholine bromide is a Commodity code that in recent state and local activity does not appear to align with actual procurement needs. The two recent opportunities tagged under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—involve pharmaceutical supply, pharmacy benefit management, and overdose-reversal products, none of which match the scope of hexcarbacholine bromide, a neuromuscular blocking agent used in anesthesia and surgical settings. The mismatch suggests either a cataloging error in the source data or that this code is not actively used in state and local procurement for its nominal commodity. State and local health and human services agencies appear to be the primary issuing bodies when pharmaceutical-related codes receive tagging, though the tagged opportunities here do not reflect hexcarbacholine procurement specifically.

The geographic activity identified in the recent opportunities block is limited to Florida and Texas, with no clear concentration pattern. Seminole County posted the IFB on June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source data that suggests stale or erroneous record-keeping. The Texas HHS Commission issued an exploratory RFI (not a binding solicitation) on April 3, 2026, seeking vendor information on direct pharmaceutical contracting models rather than purchasing specific pharmaceutical commodities. Given the absence of genuine hexcarbacholine bromide solicitations and the mismatch between the code label and the opportunities shown, this code shows little relevant recent activity for business development purposes.